CME sues CFTC over Kalshi perpetual futures approval

2 min read     Updated on 23 Jun 2026, 10:43 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

CME Group Inc. sued the CFTC over its approval of Kalshi's perpetual futures, citing competitive injury. Kalshi's crypto-tied products reached $8.5 billion in volume, while shares of Cboe, ICE, and Nasdaq fell. Coinbase has embraced the sector, recording over $211 billion in notional volume on similar contracts.

powered bylight_fuzz_icon
43780384

*this image is generated using AI for illustrative purposes only.

CME Group Inc. filed a lawsuit against the Commodity Futures Trading Commission last week regarding the regulator's decision to permit prediction market Kalshi to list perpetual futures. The lawsuit alleges the authorization violates federal law and has caused "textbook competitive injury" to the established exchange operator. This legal challenge highlights the growing tension between traditional financial infrastructure and emerging prediction markets offering high-leverage derivatives.

Kalshi's crypto-tied perpetual futures, or "perps," cleared $8.5 billion in volume within weeks of their launch, according to the Wall Street Journal. This rapid adoption has coincided with a decline in the share prices of incumbent exchanges. CME's Class A shares have dropped 12% since the CFTC's late-May approval. Other major exchanges have also experienced losses, reflecting market concerns about the competitive landscape.

Incumbent Exchange Performance

The following table illustrates the share price performance of major exchanges following the CFTC's approval of Kalshi's perpetual futures:

Company Ticker Exchange Share Decline
Cboe Global Markets CBOE BATS 26%
CME Group Inc. CME NASDAQ 12%
Intercontinental Exchange ICE NYSE 11%
Nasdaq Inc. NDAQ NASDAQ 9%

Mechanics and Market Risks

Perpetual futures differ from traditional futures as they never expire and allow traders to utilize significant leverage. CME CEO Terry Duffy warned at a Piper Sandler conference that traders lacking a deep understanding of these products risk getting "blown out." Traditional futures rely on margin calls where brokers request additional collateral, whereas perps utilize auto-liquidation. This mechanism sells positions automatically during sharp price drops to protect the platform, a feature that can fuel cascading selloffs. One surprise tariff announcement reportedly erased more than $19 billion in leveraged positions.

Kalshi CEO Tarek Mansour countered concerns about excessive risk, stating the platform offers leverage around six times, comparable to traditional futures. He attributed the pushback from established players to increased competition rather than product safety. "The incumbents don't like them because now there's competition," Mansour reportedly said.

Strategic Responses and Future Outlook

Wall Street remains divided on how to respond to the rise of perpetual futures. While CME has opted for litigation, other incumbents are considering adaptation. Cboe is reportedly weighing converting its continuous crypto futures into true perps, and Intercontinental Exchange indicated it would launch its own products if institutional clients demand them. Coinbase Global Inc. has already moved into this space, granting U.S. customers access to perpetual-style futures in July 2025, capped at 10x leverage on crypto. The company has also expanded its global lineup of perps tied to stock indexes, including AI, China, and defense names, with up to 20x leverage on ETF products. Coinbase reported logging over $211 billion in notional volume on perp-style contracts since that launch.

How will the outcome of CME's lawsuit against the CFTC shape the regulatory framework for other prediction markets seeking to launch high-leverage derivatives?

Will the competitive pressure from Kalshi force traditional exchanges like Cboe and ICE to accelerate their own perpetual futures product launches?

What systemic risks could the auto-liquidation mechanisms of perpetual futures pose to broader market stability during periods of extreme volatility?

like16
dislike

KBW upgrades CME Group to Outperform, keeps $305 target

0 min read     Updated on 18 Jun 2026, 11:13 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Keefe, Bruyette & Woods analyst Chris Allen upgraded CME Group from Market Perform to Outperform, maintaining the price target at $305.

powered bylight_fuzz_icon
43350210

*this image is generated using AI for illustrative purposes only.

Keefe, Bruyette & Woods analyst Chris Allen upgraded CME Group to Outperform from Market Perform, maintaining the price target at $305. The rating change reflects a more positive outlook on the exchange operator's performance.

Rating and Target Details

The upgrade shifts the stock's status from Market Perform to Outperform. Despite the rating change, the price target remains steady at $305.

Metric Previous Current
Rating Market Perform Outperform
Price Target $305 $305

What specific factors drove the shift in outlook despite the unchanged price target?

How might CME Group's earnings performance evolve in the upcoming quarters?

What market conditions could further support or challenge the upgrade?

like19
dislike

More News on CME Group Inc